Development Agreement With Astrazeneca R&D China For Personalized MRD Tests For Solid Tumors In China
30/11/2021 03:05
Nov 29 (Reuters) - Genetron Holdings Ltd GTH.O :
* GENETRON HEALTH ANNOUNCES CO-DEVELOPMENT AGREEMENT WITH
ASTRAZENECA RESEARCH AND DEVELOPMENT CHINA FOR PERSONALIZED MRD
TESTS FOR SOLID TUMORS IN CHINA
* UNDER AGREEMENT, COMPANIES WILL JOINTLY INVEST CAPITAL FOR
THIS
COLLABORATION
* JOINT COMMITTEE WILL BE ESTABLISHED TO OVERSEE PRODUCT
DEVELOPMEN
Source text for Eikon: ID:nGNX5934Ht
Further company coverage: GTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genetron Holdings
See all newsBrief: Genetron Holdings Requested That Trading Of Its ADSs On Nasdaq Be Suspended As Of Close Of Trading On March 28, 2024
U.S. STOCKS ON THE MOVE-Cerevel Therapeutics, Scholar Rock, Helius
U.S. STOCKS ON THE MOVE-Scholar Rock, Target, LL Flooring
U.S. STOCKS ON THE MOVE-First Solar, Genetron, Viasat
Genetron surges on $126 mln deal to go private